Xenon Pharmaceuticals

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xenon Pharmaceuticals excels in epilepsy treatment with strong IP strategy

Xenon Pharmaceuticals demonstrated strong performance and promising efficacy data for XEN1101 in epilepsy treatment, supported by a robust IP strategy and CNS penetration.
While facing challenges in patient enrollment and rising expenses, the company is exploring new therapeutic areas and potential milestone payments through partnerships.
Opportunities lie in expanding XEN1101's market reach, establishing a leadership position in epilepsy treatment, and navigating uncertainties in pediatric indications and generic competition.

Xenon Pharmaceuticals advances epilepsy program amid financial stability and challenges

Xenon Pharmaceuticals showcased progress in their epilepsy program and financial stability, while addressing challenges in enrollment dynamics and competitive pressures.
The company's focus on managing R&D expenses and upcoming milestones reflects a strategic approach to advancing their clinical programs.
Opportunities in the epilepsy market and ongoing formulation development for pediatric patients position Xenon for potential growth and innovation.

Xenon Pharmaceuticals excels in trials and finances, eyes global expansion

Xenon Pharmaceuticals showcases strong performance in key trials and financial stability, supported by positive market reception and strategic leadership additions.
While facing challenges in trial completion and enrollment trends, the company has opportunities to expand market reach, innovate in treatment approaches, and explore global partnerships.
Overall, Xenon's focus on advancing novel therapies for neurological disorders positions it well for future growth and success in the competitive pharmaceutical landscape.

Xenon Pharmaceuticals advances epilepsy and MDD treatments, poised for growth

Xenon Pharmaceuticals showcased strong performance in advancing XEN1101 for epilepsy and MDD treatments, backed by extensive data and strategic partnerships.
While facing challenges in enrollment timelines and technical complexities, the company is well-positioned financially and strategically for future growth.
Opportunities abound in addressing unmet needs, expanding drug applications, and advancing new molecules into clinical development.
Overall, Xenon Pharmaceuticals' Q3 earnings call highlighted a promising outlook for drug development and market positioning.

Xenon Pharmaceuticals excels in Q4, poised for growth in epilepsy and MDD

Xenon Pharmaceuticals showcased strong financials, program advancements, and market insights in Q4 2023, positioning the company well for future growth.
The company's focus on safety, tolerability, and efficacy in MDD treatment, along with leveraging learnings across programs, demonstrates strategic foresight.
While facing challenges in R&D spend allocation and regulatory discussions, Xenon can capitalize on opportunities for operational efficiency and market expansion.
Investor interest in Xenon's pipeline and the potential of its programs in epilepsy and MDD highlight a promising trajectory for the company.

Xenon Pharmaceuticals reports strong Q1 performance and addresses market needs

Xenon Pharmaceuticals is well-positioned with a strong financial base and promising pipeline.
The company faces challenges in conducting well-powered MDD trials and addressing market needs.
Opportunities lie in the substantial unmet need in the major depressive market and azetukalner's potential benefits.
Strategic planning and FDA alignment support Xenon's progress in key therapeutic areas.

Xenon Pharmaceuticals excels in Q3, poised for groundbreaking treatments

Xenon Pharmaceuticals demonstrated strong financial performance and progress in developing azetukalner for epilepsy and major depressive disorder.
Confidence in the lead product's potential for groundbreaking treatments was evident, supported by ongoing outreach efforts and future milestones.
While facing challenges in addressing complex analyst inquiries and navigating regulatory requirements, Xenon Pharmaceuticals is well-positioned to capitalize on opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xenon Pharmaceuticals, Inc. (XENE) CEO Simon Pimstone on Q4 2019 Results - Earnings Call Transcript

Editas Medicine

Roche Holding AG

If you can handle the uncertainty, these small-cap stocks can make you very wealthy.

3 High-Risk, High-Reward Stocks That Have Massive Upside Potential

BURNABY, British Columbia, Feb.  14, 2020  (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that the underwriters of its previously announced public offering of 3,750,000 common shares, which initially closed on January 27, 2020, have exercised in full their option to purchase an additional 562,500 common shares at the public offering price of $16.00 per share, raising additional gross proceeds of $9.0 million and increasing the total gross proceeds of the public offering to $69.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon. 

Xenon Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares

Aurinia Pharmaceuticals

Zymeworks Inc

These developers of drugs for cancer, neurological conditions, and rare diseases may boost risk-taking investors' portfolios.

3 Canadian Biotechs to Consider Buying Today

Xenon Pharmaceuticals Is Poised For Significant Progress In 2020

BURNABY, British Columbia, Jan.  27, 2020  (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced public offering of 3,750,000 common shares pursuant to its existing shelf registration statement at a public offering price of $16.00 per share. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, were $60.0 million. In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days from January 22, 2020 to purchase up to an additional 562,500 common shares at the public offering price, less the underwriting discounts and commissions.

Xenon Pharmaceuticals Announces Closing of its $60.0 Million Public Offering of Common Shares

ACM Research

Morgan Stanley

Signet Jewelers

Top Ranked Momentum Stocks to Buy for January 24th

Does Xenon Pharmaceuticals (XENE) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Xenon Pharmaceuticals (XENE) is a Great Choice

BURNABY, British Columbia, Jan.  22, 2020  (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 3,750,000 common shares pursuant to its existing shelf registration statement at a public offering price of $16.00 per share. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $60.0 million. In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days to purchase up to an additional 562,500 common shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about January 27, 2020, subject to customary closing conditions.

Xenon Pharmaceuticals Announces Pricing of $60.0 Million Public Offering of Common Shares

Xenon   ’   s Proprietary Programs Continue to Advance with Multiple Mid to Late Stage Clinical Trials    Anticipated to be Underway in 2020

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update

As of late, it has definitely been a great time to be an investor in Xenon Pharmaceuticals.

Will Xenon Continue to Surge Higher?

Xenon Pharmaceuticals, Inc. (XENE) CEO Simon Pimstone on Q3 2019 Results - Earnings Call Transcript

Xenon Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Xenon Sees Hammer Chart Pattern: Time to Buy?

BURNABY, British Columbia, Sept.  25, 2019  (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present a corporate update at the 2019 Cantor Global Healthcare Conference in New York, NY on Wednesday, October 2, 2019 at 7:45 am ET.

Xenon Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Announces Appointment of Shelley McCloskey as Senior Vice President, Human Resources

Xenon Pharmaceuticals, Inc. (XENE) CEO Simon Pimstone on Q2 2019 Results - Earnings Call Transcript

Xenon Pharmaceuticals (XENE) CEO Simon Pimstone on Q1 2019 Results - Earnings Call Transcript

Shares of Xenon Pharmaceuticals rose by as much as 150% a couple quarters after my May 2018 Reader Inquiry piece was published (thanks to ROTY member XavierD for bringing it to my attention).

News for Xenon Pharmaceuticals Stock (XENE)